STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s

STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s

311799

STAR Compounds Show Potential to Treat GBA1-linked Parkinson’s

Gain Therapeutics announced that preclinical studies with two of its compounds, GT-02287 and GT-02329, showed they could reduce the alpha-synuclein aggregates that characterize Parkinson’s and increase glucocerebrosidase protein levels in cell models of Parkinson’s and Gaucher disease. GT-02287 and GT-02329 are known as STARs, which stands for structurally targeted allosteric regulators. These regulators are designed to help mutated proteins fold correctly and recover their function. The preclinical studies, conducted at the University of Maryland School of Medicine…

You must be logged in to read/download the full post.